SCHEMBL25880866

SCHEMBL25880866

Clc1cc(OCCCBr)c(Cl)nn1

nearest known ligand 0.36

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.36
S1PR4 O95977 1/20 0.30
KDM4E B2RXH2 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25880892 0.81 TDP1 (0.36) TDP1S1PR4LMNA
SCHEMBL25880792 0.79 ENPP1 (0.43) TDP1S1PR4KDM4E
SCHEMBL22445196 0.79 TDP1 (0.38) TDP1
SCHEMBL2767989 0.79 TDP1 (0.38) TDP1S1PR4LMNA
SCHEMBL30310964 0.79 TDP1 (0.38) TDP1S1PR4LMNA
SCHEMBL30936658 0.79 TDP1 (0.38) TDP1
SCHEMBL20839734 0.78 PLAU (0.41) TDP1S1PR4LMNA
SCHEMBL30042712 0.76 TDP1 (0.35) TDP1LMNA
SCHEMBL25880994 0.75 KDM4E (0.36) TDP1S1PR4KDM4E
SCHEMBL25880894 0.75 TDP1 (0.32) TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-07-20 US disclosed
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING RBM17, SF3B1, SF3B5 TDP1 387/4885S1PR4 3133/4885KDM4E 2588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.